Tuesday, April 23, 2019 1:29:13 PM
your last post says they are awaiting "last bit of red tape" before enrollment begins. for you, does that mean all else is in place to get going, including $$ needed? do you know if they have been identifying potential candidates in this "down time" or will that still need to be done? i remember that finding and enrolling qualified potential candidates for ph 1 was not easy...and part of the reason ph 1b was cut short, i think.
also, any thoughts on what might be happening with ph1 studies for other indications the company has mentioned...?
i know these are difficult questions...and the company is relatively closed mouthed about much of it as they probably should be. i am a longtime investor and believe in the enormous potential of tlt's ip and approach. the patience required, however, can be frustrating sometimes. (that's certainly true with other dev. stage companies...not just tlt)
if you're willing -- or anyone else out there --what's your take on some of the above?
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM